Shift Pharmaceuticals

Shift Pharmaceuticals, a privately held company developing antisense oligonucleotides (ASOs) as therapeutic candidates for a variety of genetic disorders. Rather than alleviating certain disease side effects, these molecules “SHIFT” the body’s natural protein production back into alignment effectively addressing the core cause of the disease.

Shift is investigating the use of these ASOs to treat CMT1A, which is caused by a duplication in the PMP22 gene. ASOs can alter RNA and reduce, restore or modify protein expression.